Susceptibility Genes Associated with Multiple Primary Cancers
With advancements in treatment and screening techniques, we have been witnessing an era where more cancer survivors harbor multiple primary cancers (MPCs), affecting approximately one in six patients. Identifying MPCs is crucial for tumor staging and subsequent treatment choices. However, the curren...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/24/5788 |
| _version_ | 1797381650845270016 |
|---|---|
| author | Mengyao Lu Xuemei Zhang Qian Chu Yuan Chen Peng Zhang |
| author_facet | Mengyao Lu Xuemei Zhang Qian Chu Yuan Chen Peng Zhang |
| author_sort | Mengyao Lu |
| collection | DOAJ |
| description | With advancements in treatment and screening techniques, we have been witnessing an era where more cancer survivors harbor multiple primary cancers (MPCs), affecting approximately one in six patients. Identifying MPCs is crucial for tumor staging and subsequent treatment choices. However, the current clinicopathological criteria for clinical application are limited and insufficient, making it challenging to differentiate them from recurrences or metastases. The emergence of next-generation sequencing (NGS) technology has provided a genetic perspective for defining multiple primary cancers. Researchers have found that, when considering multiple tumor pairs, it is crucial not only to examine well-known essential mutations like MLH1/MSH2, EGFR, PTEN, BRCA1/2, CHEK2, and TP53 mutations but also to explore certain pleiotropic loci. Moreover, specific deleterious mutations may serve as regulatory factors in second cancer development following treatment. This review aims to discuss these susceptibility genes and provide an explanation of their functions based on the signaling pathway background. Additionally, the association network between genetic signatures and different tumor pairs will be summarized. |
| first_indexed | 2024-03-08T20:55:29Z |
| format | Article |
| id | doaj.art-2887923a98e647caa90f1b75b7e36d03 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T20:55:29Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-2887923a98e647caa90f1b75b7e36d032023-12-22T13:58:52ZengMDPI AGCancers2072-66942023-12-011524578810.3390/cancers15245788Susceptibility Genes Associated with Multiple Primary CancersMengyao Lu0Xuemei Zhang1Qian Chu2Yuan Chen3Peng Zhang4Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaWith advancements in treatment and screening techniques, we have been witnessing an era where more cancer survivors harbor multiple primary cancers (MPCs), affecting approximately one in six patients. Identifying MPCs is crucial for tumor staging and subsequent treatment choices. However, the current clinicopathological criteria for clinical application are limited and insufficient, making it challenging to differentiate them from recurrences or metastases. The emergence of next-generation sequencing (NGS) technology has provided a genetic perspective for defining multiple primary cancers. Researchers have found that, when considering multiple tumor pairs, it is crucial not only to examine well-known essential mutations like MLH1/MSH2, EGFR, PTEN, BRCA1/2, CHEK2, and TP53 mutations but also to explore certain pleiotropic loci. Moreover, specific deleterious mutations may serve as regulatory factors in second cancer development following treatment. This review aims to discuss these susceptibility genes and provide an explanation of their functions based on the signaling pathway background. Additionally, the association network between genetic signatures and different tumor pairs will be summarized.https://www.mdpi.com/2072-6694/15/24/5788multiple primary cancerssusceptibility genesgenetic predispositionsecond cancernext-generation sequencing |
| spellingShingle | Mengyao Lu Xuemei Zhang Qian Chu Yuan Chen Peng Zhang Susceptibility Genes Associated with Multiple Primary Cancers Cancers multiple primary cancers susceptibility genes genetic predisposition second cancer next-generation sequencing |
| title | Susceptibility Genes Associated with Multiple Primary Cancers |
| title_full | Susceptibility Genes Associated with Multiple Primary Cancers |
| title_fullStr | Susceptibility Genes Associated with Multiple Primary Cancers |
| title_full_unstemmed | Susceptibility Genes Associated with Multiple Primary Cancers |
| title_short | Susceptibility Genes Associated with Multiple Primary Cancers |
| title_sort | susceptibility genes associated with multiple primary cancers |
| topic | multiple primary cancers susceptibility genes genetic predisposition second cancer next-generation sequencing |
| url | https://www.mdpi.com/2072-6694/15/24/5788 |
| work_keys_str_mv | AT mengyaolu susceptibilitygenesassociatedwithmultipleprimarycancers AT xuemeizhang susceptibilitygenesassociatedwithmultipleprimarycancers AT qianchu susceptibilitygenesassociatedwithmultipleprimarycancers AT yuanchen susceptibilitygenesassociatedwithmultipleprimarycancers AT pengzhang susceptibilitygenesassociatedwithmultipleprimarycancers |